These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 22172509)

  • 41. [Progress on the vaccine for anthrax].
    Zhan DW; Wang P; Wang LC; Zhang ZS
    Wei Sheng Wu Xue Bao; 2005 Feb; 45(1):149-52. PubMed ID: 15847185
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparability of ELISA and toxin neutralization to measure immunogenicity of Protective Antigen in mice, as part of a potency test for anthrax vaccines.
    Parreiras PM; Sirota LA; Wagner LD; Menzies SL; Arciniega JL
    Vaccine; 2009 Jul; 27(33):4537-42. PubMed ID: 19501205
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of the immune response induced by a nasal anthrax vaccine based on the protective antigen protein in anaesthetized and non-anaesthetized mice.
    Sloat BR; Cui Z
    J Pharm Pharmacol; 2006 Apr; 58(4):439-47. PubMed ID: 16597361
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Nasal immunization with a dual antigen anthrax vaccine induced strong mucosal and systemic immune responses against toxins and bacilli.
    Sloat BR; Cui Z
    Vaccine; 2006 Sep; 24(40-41):6405-13. PubMed ID: 16828937
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Development of ELISA based on Bacillus anthracis capsule biosynthesis protein CapA for naturally acquired antibodies against anthrax.
    Zorigt T; Furuta Y; Simbotwe M; Ochi A; Tsujinouchi M; Shawa M; Shimizu T; Isoda N; Enkhtuya J; Higashi H
    PLoS One; 2021; 16(10):e0258317. PubMed ID: 34634075
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Potentiation of an anthrax DNA vaccine with electroporation.
    Luxembourg A; Hannaman D; Nolan E; Ellefsen B; Nakamura G; Chau L; Tellez O; Little S; Bernard R
    Vaccine; 2008 Sep; 26(40):5216-22. PubMed ID: 18462850
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine.
    Little SF; Ivins BE; Fellows PF; Pitt ML; Norris SL; Andrews GP
    Vaccine; 2004 Jan; 22(3-4):422-30. PubMed ID: 14670324
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The detection of protective antigen (PA) associated with spores of Bacillus anthracis and the effects of anti-PA antibodies on spore germination and macrophage interactions.
    Cote CK; Rossi CA; Kang AS; Morrow PR; Lee JS; Welkos SL
    Microb Pathog; 2005; 38(5-6):209-25. PubMed ID: 15925272
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Advances in the development of next-generation anthrax vaccines.
    Friedlander AM; Little SF
    Vaccine; 2009 Nov; 27 Suppl 4():D28-32. PubMed ID: 19837282
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Protective activity and immunogenicity of two recombinant anthrax vaccines for veterinary use.
    Fasanella A; Tonello F; Garofolo G; Muraro L; Carattoli A; Adone R; Montecucco C
    Vaccine; 2008 Oct; 26(45):5684-8. PubMed ID: 18775462
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The US capitol bioterrorism anthrax exposures: clinical epidemiological and immunological characteristics.
    Doolan DL; Freilich DA; Brice GT; Burgess TH; Berzins MP; Bull RL; Graber NL; Dabbs JL; Shatney LL; Blazes DL; Bebris LM; Malone MF; Eisold JF; Mateczun AJ; Martin GJ
    J Infect Dis; 2007 Jan; 195(2):174-84. PubMed ID: 17191162
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacious, nontoxigenic Bacillus anthracis spore vaccines based on strains expressing mutant variants of lethal toxin components.
    Mendelson I; Gat O; Aloni-Grinstein R; Altboum Z; Inbar I; Kronman C; Bar-Haim E; Cohen S; Velan B; Shafferman A
    Vaccine; 2005 Dec; 23(48-49):5688-97. PubMed ID: 16039760
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Additional conjugation methods and immunogenicity of Bacillus anthracis poly-gamma-D-glutamic acid-protein conjugates.
    Kubler-Kielb J; Liu TY; Mocca C; Majadly F; Robbins JB; Schneerson R
    Infect Immun; 2006 Aug; 74(8):4744-9. PubMed ID: 16861662
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunoproteomically identified GBAA_0345, alkyl hydroperoxide reductase subunit C is a potential target for multivalent anthrax vaccine.
    Kim YH; Kim KA; Kim YR; Choi MK; Kim HK; Choi KJ; Chun JH; Cha K; Hong KJ; Lee NG; Yoo CK; Oh HB; Kim TS; Rhie GE
    Proteomics; 2014 Jan; 14(1):93-104. PubMed ID: 24273028
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The capsule of Bacillus anthracis behaves as a thymus-independent type 2 antigen.
    Wang TT; Lucas AH
    Infect Immun; 2004 Sep; 72(9):5460-3. PubMed ID: 15322045
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Development of a highly efficacious vaccinia-based dual vaccine against smallpox and anthrax, two important bioterror entities.
    Merkel TJ; Perera PY; Kelly VK; Verma A; Llewellyn ZN; Waldmann TA; Mosca JD; Perera LP
    Proc Natl Acad Sci U S A; 2010 Oct; 107(42):18091-6. PubMed ID: 20921397
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin.
    Fellows PF; Linscott MK; Ivins BE; Pitt ML; Rossi CA; Gibbs PH; Friedlander AM
    Vaccine; 2001 Apr; 19(23-24):3241-7. PubMed ID: 11312020
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cutting Edge: IFN-gamma-producing CD4 T lymphocytes mediate spore-induced immunity to capsulated Bacillus anthracis.
    Glomski IJ; Corre JP; Mock M; Goossens PL
    J Immunol; 2007 Mar; 178(5):2646-50. PubMed ID: 17312104
    [TBL] [Abstract][Full Text] [Related]  

  • 59.
    Sharma S; Bhatnagar R; Gaur D
    Front Immunol; 2020; 11():462. PubMed ID: 32296419
    [No Abstract]   [Full Text] [Related]  

  • 60. Evaluation of immunogenicity and efficacy of anthrax vaccine adsorbed for postexposure prophylaxis.
    Ionin B; Hopkins RJ; Pleune B; Sivko GS; Reid FM; Clement KH; Rudge TL; Stark GV; Innes A; Sari S; Guina T; Howard C; Smith J; Swoboda ML; Vert-Wong E; Johnson V; Nabors GS; Skiadopoulos MH
    Clin Vaccine Immunol; 2013 Jul; 20(7):1016-26. PubMed ID: 23658392
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.